为阿尔茨海默病及相关痴呆症研究建立多生物标志物低容量面板基准

IF 13 1区医学 Q1 CLINICAL NEUROLOGY

Alzheimer's & Dementia Pub Date : 2024-11-22 DOI:10.1002/alz.14413

Laura Ibanez, Menghan Liu, Aleksandra Beric, Jigyasha Timsina, Pat Kohlfeld, Kristy Bergmann, Joey Lowery, Nick Sykora, Brenda Sanchez-Montejo, Will Brock, John P. Budde, Randall J. Bateman, Nicolas Barthelemy, Suzanne E. Schindler, David M. Holtzman, Tammie L. S. Benzinger, Chengjie Xiong, Rawan Tarawneh, Krista Moulder, John C. Morris, Yun Ju Sung, Carlos Cruchaga

{"title":"为阿尔茨海默病及相关痴呆症研究建立多生物标志物低容量面板基准","authors":"Laura Ibanez, Menghan Liu, Aleksandra Beric, Jigyasha Timsina, Pat Kohlfeld, Kristy Bergmann, Joey Lowery, Nick Sykora, Brenda Sanchez-Montejo, Will Brock, John P. Budde, Randall J. Bateman, Nicolas Barthelemy, Suzanne E. Schindler, David M. Holtzman, Tammie L. S. Benzinger, Chengjie Xiong, Rawan Tarawneh, Krista Moulder, John C. Morris, Yun Ju Sung, Carlos Cruchaga","doi":"10.1002/alz.14413","DOIUrl":null,"url":null,"abstract":"In the research setting, obtaining accurate established biomarker measurements and maximizing use of the precious samples is key. Accurate technologies are available for Alzheimer's disease (AD), but no platform can measure all the established and emerging biomarkers in one run. The NUcleic acid Linked Immuno-Sandwich Assay (NULISA) is a technology that requires 15 µL of sample to measure more than 100 analytes.","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"7 1","pages":""},"PeriodicalIF":13.0000,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Benchmarking of a multi-biomarker low-volume panel for Alzheimer's disease and related dementia research\",\"authors\":\"Laura Ibanez, Menghan Liu, Aleksandra Beric, Jigyasha Timsina, Pat Kohlfeld, Kristy Bergmann, Joey Lowery, Nick Sykora, Brenda Sanchez-Montejo, Will Brock, John P. Budde, Randall J. Bateman, Nicolas Barthelemy, Suzanne E. Schindler, David M. Holtzman, Tammie L. S. Benzinger, Chengjie Xiong, Rawan Tarawneh, Krista Moulder, John C. Morris, Yun Ju Sung, Carlos Cruchaga\",\"doi\":\"10.1002/alz.14413\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In the research setting, obtaining accurate established biomarker measurements and maximizing use of the precious samples is key. Accurate technologies are available for Alzheimer's disease (AD), but no platform can measure all the established and emerging biomarkers in one run. The NUcleic acid Linked Immuno-Sandwich Assay (NULISA) is a technology that requires 15 µL of sample to measure more than 100 analytes.\",\"PeriodicalId\":7471,\"journal\":{\"name\":\"Alzheimer's & Dementia\",\"volume\":\"7 1\",\"pages\":\"\"},\"PeriodicalIF\":13.0000,\"publicationDate\":\"2024-11-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Alzheimer's & Dementia\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/alz.14413\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer's & Dementia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/alz.14413","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

摘要

在研究环境中，获得准确的既定生物标志物测量结果并最大限度地利用珍贵的样本是关键所在。目前已有针对阿尔茨海默病（AD）的精确技术，但没有一个平台能在一次运行中测量所有已确定的和新出现的生物标记物。NUcleic acid 链接免疫三明治分析法 (NULISA) 是一种只需 15 µL 样品就能测量 100 多种分析物的技术。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Benchmarking of a multi-biomarker low-volume panel for Alzheimer's disease and related dementia research

In the research setting, obtaining accurate established biomarker measurements and maximizing use of the precious samples is key. Accurate technologies are available for Alzheimer's disease (AD), but no platform can measure all the established and emerging biomarkers in one run. The NUcleic acid Linked Immuno-Sandwich Assay (NULISA) is a technology that requires 15 µL of sample to measure more than 100 analytes.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Alzheimer's & Dementia 医学-临床神经学

CiteScore

14.50

自引率

5.00%

发文量

299

审稿时长

3 months

期刊介绍： Alzheimer's & Dementia is a peer-reviewed journal that aims to bridge knowledge gaps in dementia research by covering the entire spectrum, from basic science to clinical trials to social and behavioral investigations. It provides a platform for rapid communication of new findings and ideas, optimal translation of research into practical applications, increasing knowledge across diverse disciplines for early detection, diagnosis, and intervention, and identifying promising new research directions. In July 2008, Alzheimer's & Dementia was accepted for indexing by MEDLINE, recognizing its scientific merit and contribution to Alzheimer's research.